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Using peptide aptamers to analyse 
the proteome 
Alejandro Colman-Lerner and Roger Brent 
During the 20th century, a great deal of biological knowledge came fron1 the perfection 
of n1ethods to perform manipulative transmission genetics. During the early 21 st century, 
such n1ethods will be supplemented, and perhaps sometimes supplanted, by dominant 
'genetic' n1ethods to probe the function of the proteome. 
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At the start of the 20th century, the 'rediscovery of Mendel'l 
allowed the consideration of inheritance on a rational, scien-
tific (albeit abstract) basis. During the period 1910-1920, 
T.H. Morgan and co-workers2 began to lay the groundwork 
for the practice of manipulative transmission genetics. This 
allowed researchers to collect mutants affected in a given 
genetic process, map those mutations to loci (genes), and 
further study the effects of combinations of those genes. The 
eventual linkage of genes to protein products was of course 
one of the early triumphs of molecular biology. Continuing 
improvements in transmission genetic methods, and their 
extension to more and more organisms, arguably accounted 
for the bulk of the increase in biological understanding 
during the latter half of the 20th century. 
In search of altered phenotypes 
Canonically, many classical genetic studies begin with the 
isolation of numerous mutants that affect a given trait (a 
'mutant hunt'), followed by the application of various 
techniques to give clues to the function of the mutated 
genes (Fig. 1a). The most informative mutations are typi-
cally held to be recessive mutations that result in loss of 
gene function (,hypomorphs') , with the best of these re-
sulting in complete loss offunction (,nulls '). In addition, 
the ideal mutations produce strong effects on the pheno-
type and are highly penetrant. In diplOid organisms, this 
sort of analysis works best in organisms when it is easy to 
generate and examine large numbers of F2 offspring, in 
which the recessive mutations can be homozygous and 
their effects made manifest. 
Of course, dominant mutations were always isolated too 
and, although their analysis has never been as easy (and, 
more importantly, general doctrines for working with them 
were slow to emerge), these mutations have always sup-
plemented the loss-of-function approach to understanding 
genetic pathways. Genetic analysis has also, from time to 
time, been supplemented by the use of chemical inhibitors: 
in particular, by cell-permeant, small-molecule drugs. As 
the mechanisms of action of more and more drugs have 
become known, drugs have come to be perceived as 
agents that inactivate specific protein targets. Such phar-
macological inhibitors are dominant in that they act on 
the protein even if it is encoded by, for example, both 
copies of a gene in a diploid organism. More recently, dur-
ing the past 20 years, antisense RNA and RNA derivatives 
have been developed3,4; these are also dominant. 
During the past ten years, several lines of research have 
led to the development of inactivating proteins expressed 
from members of combinatorial libraries. It is likely that 
further developments along these lines will contribute to 
the rise of a kind of dominant 'genetics' that operates at the 
level of the expressed proteins of the genome (hereafter, the 
proteome). During the early 21 st century, dominant analy-
sis of the proteome might contribute to biological under-
standing to the same extent as loss-of-function trans-
mission genetics contributed to biological understanding 
in the 20th century. 
Selection of nucleic acid and protein affinity 
reagents from combinatorial libraries 
One thread leading to dominant protein 'genetiCS' comes 
from work by Szostak et al. 5 and Gold et al. 6 These re-
searchers described the selection ofRNAs and, later, DNAs, 
from pools of random sequences that bound desired li-
gands. Successive rounds of selection, interspersed with 
rounds of mutation, resulted in the selection of agents with 
affinities in the micromolar-nanomolar range. Ellington 
and Szostak termed these molecules aptamers, from the 
Greek 'to fit' (the same root as hapten), a term that has 
entered general use. Nucleic acid aptamers are useful as 
research reagents that can recognize target proteins in vitro, 
and have the potential to be useful as drugs. 
Another thread came from methods that selected 
from combinatorial libraries proteins that bind targets. 
The best known examples of these methods are referred 
to as 'phage display ' . In these methods, libraries of 
Escherichia coli bacteriophage display different pep tides 
fused to a Viral surface protein. After selecting phages that 
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have peptides with the desired characteristics, the genetic 
material of the phage can be amplified and sequenced to 
determine the peptide sequence. Smith et 01. 7 , Dower et 
01. 8 and Devlin et 01. 9 described libraries of pep tides fused 
to the gene III protein of phage fd . Later, others described 
similar peptide libraries fused to the filamentous phage 
proteins VII, VIII and IX (Refs 1 0, 1 1), and to surface pro-
teins of phage T7 (Refs 12,13). 
There are at least three other schemes to select affinity 
peptides in vitro linked to the DNA that encodes it: (1) 
Random pep tides are displayed fused to lac repressor l4 ; 
in this scheme, the plasmid that encodes the repressor-
peptide fusion also contains a lac operator, so that the 
repressor-peptide fusion binds to the plasmid that encodes 
it. (2) The peptide is linked to the yeast Ga14 activation 
region II, allowIng selection of yeast that bear the activator-
peptide chimera in a two-hybrid assayl S. (3) Constrained 
peptides are displayed on E. coli Thioredoxin or other 
carrier proteins (TrxA), as further described below. 
One of the questions most frequently asked about 
pep tides selected by these methods is : what are they 
good for? Except for the special case in which selected 
peptides bind well to particular anti-protein antibodies 
(and whose sequence thus defines linear epitopes recog-
nized by those antibodies), pep tides selected by these 
schemes typically bind their targets with low affinity, too 
low to function in lieu of antibodies in conventional re-
search protocols. The hope that the selected pep tides 
might be useful as starting points for the design of small-
molecule drugs that mimicked their structure has faded, 
or at least proved to be difficult. However, other uses have 
either materialized or show great promise: these include 
affinity reagents in purification schemes 16, and as Signals 
that direct viral or cellular vectors to particular tissues and 
cell types 17. 18 for therapies under development 19 
Development of intracellular protein aptamers 
In 1993, John McCoy and co-workers l6 described another 
display scheme. The important feature of this approach is 
that the variable sequences are conformationally constrained 
by fusion at both ends to a platform protein. In this scheme, 
the variable region is displayed in lieu of the active site 
loop of E. coli TrxA, which is in turn displayed on the sur-
face of the major E. coli flagellar protein, FliC. Discussions 
between McCoy and Brent led to the proposal that confor-
mationally constrained peptides of variable sequence 
could be displayed by TrxA inside cells, and selected either 
to bind protein targets in two-hybrid interactor hunts , or to 
cause phenotypes directly by disrupting protein-protein 
interactions. Accordingly, we constructed three libraries 
that directed the syntheSiS in Saccharomyces cerevisiae of TrxA 
derivatives that contained constrained 20-mer variable 
regions and that did or did not carry the other moieties 
needed to work as 'preys ' in the two-hybrid system. 
In the first use of these libraries , Colas et 01. 20 began 
with human Cdk2 as bait in a two-hybrid hunt to select 
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Figure 1. Use of 
protein aptamers for 
gene and protein 
identification 
(a) Gene identifcation by F2 
loss-of-function experiments, 
A diploid organism is 
mutagenized, in this case 
Drosophila, and F1 progeny are 
generated after a cross with a 
non-mutagenized organism 
(WT). F1 progeny are crossed 
with one another, or with 
members of stocks of 
organisms that contain haploid 
deletions, to create the F2. 
F2 progeny are surveyed to 
reveal those that exhibit a 
particular mutant phenotype 
(green organisms). Mutations 
are characterized further 
(e.g, by mapping, epistasis, 
gene cloning and sequencing) 
to elucidate their function, 
(b) Whole organism protein 
identification by dominant 
protein 'genetic' experiments, 
Cells or organisms (of any 
ploidy) are 'mutagenized' by 
introducing into individuals, 
constructs that direct the 
synthesis of individual protein 
aptamers, Synthesis of the 
aptamers is induced, and the 
cells or organisms (in this case 
in the F1) that expressed 
aptamers that cause a particular 
phenotype (green organisms) 
are identified, Constructs are 
rescued from these 'mutant' 
cells or organisms, and the 
proteins and/or protein 
interactions that they target are 
identified by two-hybrid or other 
affinity techniques. These 
techniques have been 
demonstrated to work in cells 
and unicellular organisms. 
Although the figure shows how 
they might be applied to 
Drosophila, the first applications 
of these methods to multicellular 
organisms will probably be for 
those of higher ploidy (for 
example maize) and/or for 
organisms that have not been 
subjected to extensive previous 
genetic analysis (including 
organisms not of great 
economic importance to 
developed countries), in which 
loss-of-function genetics is 
unlikely to be developed, 
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TrxA-aptamer 
Figure 2. Protein 
aptamer structure 
Protein aptamers consist of a 
constant platform (constant 
region) that also carries one or 
more conformationally 
constrained peptides of variable 
sequence. The figure shows 
modified ribbon diagrams of 
two platforms (light green) and 
variable regions (yellow) . The 
structure of the V regions is 
arbitrary; in no case is an aptamer 
V-region structure known and, 
even for the best studied cases 
(anti-E2F TrxA-aptamers23) , 
there is only indirect evidence 
that any V region is structured 
before the aptamer binds the 
target. The aptamer (a) has a 
single, continuous V region 
inserted in the active site of TrxA 
(Ref. 16), whereas the aptamer 
(b) carries eight V regions 
inserted in corresponding eight 
exposed loops of the enzyme 
indol-3-phosphate synthase4o. 
Currently, TrxA aptamers have 
the highest reported affinities, 
with equilibrium dissociation 
constants in the nanomolar 
range. Abbreviation: TrxA, 
thioredoxin. 
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TrxA-variable region derivatives fused to activation domains 
('preys') that specifically interacted with CDK2. These oc-
curred in the library at a frequency of about 1 in every 
105 expressed proteins. Some, but not most, crossreacted 
with related cyclin-dependent kinases. Most inhibited 
CDK2 activity, apparently by competing for its ability to 
bind the substrate. As measured directly (by binding) and 
indirectly (by inhibition of activity), all six aptamers tested 
had equilibrium dissociation constants below 100 nM, 
and, for one of them, it was below 2 nM. The relatively 
tight binding of these agents was attributed to the fact 
that the 20-mer variable region (V) was constrained at 
both ends , thus reduCing the number of conformations 
assumed by the unbound variable region and lowering 
the en tropic cost of assuming a single conformation upon 
binding (see also Ref. 2 1 ). These agents, proteins that ex-
press variable regions constrained at both ends by a plat-
form protein, were termed peptide aptamers. Nowadays, 
these molecules are also called protein aptamers (Fig. 2). 
More than 20 TrxA peptide aptamers have since been 
identified in Single-step selections against numerous protein 
targets; one aptamer resulted from a round of mutagenesis 
of a successful V region followed by a second two-hybrid 
step using a reporter gene that demanded higher-affmity 
binding22 . In cases where affinity was measured, first round 
aptamers had Kd values tighter than 100 nM (and frequently 
in the I1.l\.1 range); for the single second round aptamer, the Kd 
value increased from 100 nM to 5 I1.l\.1 (Ref 22) . 
The selected aptamers function in vivo. Anti-Cdk2 ap-
tamers inhibit the activity of their target proteins in human 
cells2 1 and in developing Drosophila 23 . Anti-E2F aptamers af-
fect the ability ofE2F to form heterodimers with DP1 and to 
stimulate cell division in mammalian cells24. Anti-HPV16 E6 
aptamers block the anti -apoptotic activity of E6 in HPV 16 + 
cancer cells, causing cell death25 . Use of 'two-bait' two-hy-
brid systems allowed the selection of aptamers that inter-
acted specifically with one allelic form of the Harvey Ras on-
coprotein 26 and inhibited the activity of that form in 
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transformed cells (c.W Xu et oJ ., unpublished) . In each case, 
the effect of the aptamers is likely to be due to binding their 
target in vivo, thereby keeping it from interacting with one or 
more partner proteins or other molecules. Although the se-
lection is by two-hybrid, there is no reason why any of the 
surface display methods described above should not allow 
selection against larger numbers of baits in vitro. It thus seems 
likely that selection can be scaled up to isolate aptamers that 
interact with every protein encoded by a genome. 
In the above cases, the approach is a reverse 'genetic' 
one. The word' genetic ' is in quotes as expression of pep-
tide aptamers does not alter the cell's genetic material . 
However, by analogy with reverse genetic approaches 
where the word genetic is not in quotes, one begins with a 
target protein (or allelic form of a protein, or protein-pro-
tein interaction) and one inactivates it to determine its 
normal function . For example, the experiments of Butz et 
a1. 25 demonstrate that one function of HPV E6 is to inhibit 
apoptosis. This reverse genetic approach does not need to 
be restricted to protein aptamers. Recently, Shi et a1. 27 de-
scribed a pentavalent RNA aptamer directed against the 
Drosophila splicing protein BS2 that, when expressed in flies, 
inhibited BS 2 activity. RNA aptamers can be selected 
against many protein targets, can bind them tightly (many 
had Kd values below 1 nM) and can be stable in vivo28 . 
Moreover, when aptamers come to be used as 'reverse ge-
netic' reagents in vertebrate organisms, it is possible that 
nucleic-acid derived aptamers might be only weakly im-
munogenic, whereas animals expressing protein aptamers 
might need to be made tolerant to them. 
Intracellular protein aptamers as forward 
'genetic'reagents 
More recently, aptamers have been used in forward' gen-
etic' experiments (Fig. 1 b) to identify proteins and protein 
interactions that affect biological pathways. The first pub-
lished uses of this approach were in the yeast S. cerevisiae to 
analyse the response to mating pheromone29- 3 ! and the 
spindle checkpoint3 !. These groups isolated aptamers 
[displayed, respectively, by GFP (Ref. 32), TrxA and 
Staphylococcus aureus nuclease] that blocked cell-cycle arrest 
caused either by mating pheromone or by the spindle 
checkpoint, and then used the aptamers as baits and/or 
preys in two-hybrid experiments to find the proteins 
targeted by those aptamers. This approach has been used 
in E. coli by Blum et a1. 33 and extended to mammalian cells 
by G. Nolan and co-workers at Stanford and at Rigel, Inc. 
(pers. commun.) and by ourselves. 
Several lines of evidence demonstrate the power of 
the combination of two-hybrid and aptamer technology. 
First,itS use resulted in the identification of a protein , 
Cbk 1, whose loss diminishes but does not abolish the 
mating response. Before this analysis, Cbk 1 was not 
known to function in the pathway30. This finding illus-
trates that aptamer technology can be useful for the study 
of cellular processes that have been extensively explored 
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by conventional genetics. The authors showed that most of 
the aptamers targeted the same genetic step in the signal 
transduction pathway: the activation of Ste 1 1, a prototype 
for the mitogen-activated protein kinase kinase kinase in 
mammalian cells. The finding that this step in this pathway 
is most sensitive to perturbation by diminution of function 
by aptamers suggests that the analogous step in mammalian 
pathways would be a good target for drug discovery efforts. 
Second, as ordered panels of yeast bearing appropriately 
derivatized proteins for interaction mating two-hybrid 
experiments34 are generated for more organisms35 (R. Finley, 
pers. commun.), it will become easier to identify pro-
teins targeted by the aptamers to produce their effects . 
Third (as mentioned previously), the use of two-hybrid 
makes it easy to mutagenize the DNA encoding the ap-
tamer variable region and select tighter-binding variants 
(B.A. Cohen, PhD thesis, Harvard University, 1998). The 
ability to generate such tighter-binding aptamers is help-
ful in making aptamer derivatives that can change the 
subcellular localization of their targets and/or decorate 
the targets with ubiquitin moieties22 . 
Fourth, the use of appropriately configured two-hybrid 
constructs, in at least some cases, allows the investigator 
to define not just the protein, but the protein interaction 
that is targeted30 . 
Finally, we imagine that the use of mixed pools of ap-
tamers targeted to different subcellular compartments or 
derivatized with different effector functions will make it 
possible to generate some knowledge about the proteins 
that function in a given process, even before the specific 
targets of those aptamers are identified from ordered 
two-hybrid arrays or other interaction techniques. 
Future developments and their impact on 
biological research 
One reason that protein aptamer technologies are develop-
ing rapidly is that they make direct use of biology's means 
of inventing and perfecting deSigns : namely, generation of 
diversity followed by selection for fitness according to some 
criterion - followed by, if deSired, improvement of the 
progeny by repeating this process. One foreseeable conse-
quence of continued peptide aptamer development is their 
selection against a great many more targets, and their 
eventual adoption as affinity reagents in lieu of antibodies 
in 'immunological' techniques. Antibodies are wonderful 
affinity molecules, but the last Significant improvement in 
this field, the invention of monoclonal antibodies, dates 
back to 1975 (Ref. 36). Since that time, there have been 
numerous schemes to generate antibody diversity and 
select antibodies ex vivo. Although space does not permit a 
comprehensive review of these methods, some of them 
(see, for example, the work of Knappik et alY) have allowed 
the selection of Single chain antibodies with picomolar 
dissociation constants. For several reasons, including the 
extent to which incremental advances have tended to be-
come encrusted with patents, the defense of that intellectual 
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property by undercapitalized commercial firms, and the 
fact that the business models of those firms normally require 
that they license and sell what they produce to a small 
number of large pharmaceutical companies, none of these 
approaches has gained wide adoption. For use in lieu of 
antibodies, aptamers must bind strongly and speCifically 
and be able, in principle, to bind any protein surface. 
Compare a TrxA 20-merV region aptamer with the two-
chain, [3-sheet-dominated, 6-variable regions (totalling 
more than 50 reSidues) of an immunoglobulin Fab. 
To gain the needed affinity, specificity and universality, 
researchers will need to explore different configurations of 
platforms and constrained variable regions (Fig. 2). 
Peptide aptamers can be selected in vitro. The puromycin 
crosslinking in vitro peptide display scheme of Roberts et aP8 
allows selection of three variable region fibronectin-based 
aptamers from large (greater than 10 12) synthetiC pools 
(B. Kreider, pers. commun.). Although that particular tech-
nology is largely proprietary to a Single company, Phylos, 
the overall ideas are not, and in ten years time, it is likely 
that antibodies generated in vivo will be out-competed by 
these more modern (and in the case of aptamers, Simpler) 
protein-based agents. Such development would free large 
numbers of mice and rabbits from their involuntary ser-
vice to human research, diagnosis and therapy. It will also 
allow the generation of affinity reagents against the entire 
complement of genome-encoded proteins, specifically pep-
tide aptamers directed against the products of different 
splice variants and against modification states of the pro-
teins. Development of these affinity reagents will, in turn, 
enable the construction of new diagnostiC devices and 
research instruments to survey entire proteomes. 
It is likely that aptamers will find use in other aspects of 
biological discovery and analysis. A particularly good ex-
ample is the case of redundant gene function . As is now 
Widely appreCiated, vertebrate animals are, roughly speak-
ing, products of an ancestral gene quadruplication, and the 
four (or three, or five) copies of each gene frequently have 
redundant functions39 . Armed with the right aptamers and 
the right selection schemes, it should be possible to gener-
ate aptamers that speCifically crossreact with and inactivate 
the function of all members of a given protein family. Such 
aptamers can then be used to determine the function of an 
entire family of proteins in a single study rather than serially 
inactivating the genes and performing the necessary crosses. 
Another possible development is highly speculative, but 
worth mentioning. Genetic analysis is easiest when applied 
to strong, penetrant phenotypes. In fact, we can even posit 
a straw-man geneticist, who would say that no gene is 
weakly acting or incompletely penetrant if it is in the right 
background, and if the right phenotype can be found. In 
the near future, however, there are at least two reasons why 
biologists might need to grapple with phenotypes affected 
by genes whose action might be weak and incompletely 
penetrant. One reason is simply the fact that there are huge 
piles (soon to grow vastly larger) of quantitative genetic 
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data (consider SNPs) that correlate with quantitative traits 
of interest (consider the odds of developing a particular 
malady). For some of these traits, there is no relevant model 
organism tractable to loss-of-function genetics. Another 
reason is that, even if we could devise phenotypes that 
would allow selection of decisive mutants for all important 
processes in, for example, mice, the whole process would 
take a great deal of effort and a very long time. We have 
argued that protein-family-specific peptide aptamers might 
proVide a useful shortcut to the analysis of groups of genes 
of redundant function. We also believe that they will playa 
part in a necessary task - the analysis of gene products that 
quantitatively affect phenotypes. Comprehensive, scalable 
methods to address such traits in important organisms will 
increasingly be needed. The early 20th century taught us 
how to identify some genes in some organisms. The end of 
the 20th century taught us how to identify all the genes in 
any organism. The corresponding spirit of the early 21st 
century may well teach us how, in any organism, to identify 
all the gene products that contribute to a given trait. 
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